Successful utilization of SCT modalities often requires utilization of both red cell and platelet transfusions. In this retrospective evaluation of clinical factors affecting transplant engraftment and transfusion utilization at a single transplant center in 505 patients from 2005 through 2009, we found that graft type, donor type and the conditioning regimen intensity significantly affected both the neutrophil engraftment time (Po0.001) and the platelet engraftment time (Po0.001). SCT patients required an average of 6.2 red cell units, and 7.9 platelet transfusions in the first 100 days with a wide s.d. Among auto-SCT patients, 5% required neither RBC nor platelet transfusions. Some reduced-intensity transplants were also associated with no transfusion need, and in allogeneic transplants, conditioning regimen intensity was positively correlated with platelet transfusion events as assessed by multivariate analysis. Other patient characteristics such as gender, graft type, donor type, underlying disease and use of TBI were all independently associated with transfusion needs in SCT patients. Further studies are required to understand the means to minimize transfusions and potential related complications in SCT patients.
INTRODUCTION
Hematopoietic SCT continues to be an effective therapy for many marrow disorders and hematologic malignancies. 1 Conditioning regimens utilized to prepare patients for hematopoietic SCT uniformly result in suppression of marrow function, sometimes leading to prolonged recovery of neutrophils and platelets. 2, 3 Because increases in infection, bleeding and transfusionassociated morbidity can result from delayed engraftment, an important objective in designing treatment plans is to minimize the duration of cytopenias. 4 The use of PBSC grafts as compared with marrow graft sources has shortened white cell and platelet count nadirs as has the use of G-CSF after autograft infusion to speed recovery of neutrophils. G-CSFs have also been utilized after allografting and with cord blood transplant, but more controversy surrounds their use in those settings. 5 Conditioning regimens for hematopoietic SCT vary in degree or the intensity of myeloablative and immune suppressive potential. Some regimens incorporate total body radiation, whereas others use combination chemotherapy without total body radiation. Additionally, transplants may be from autologous, allogeneic or umbilical cord blood sources. In spite of advantages of umbilical cord blood in shortened stem cell procurement times and decreased GVHD incidence and severity, 6 most evidence indicates delayed platelet engraftment times and, in some cases, delayed time to neutrophil engraftment. 7 The significance of delayed neutrophil and platelet engraftment times on overall survival has been reported, 8 but the extent to which engraftment times are affected by demographic, therapeutic and other clinical factors is poorly understood. In this retrospective study of consecutive patients undergoing SCT at the University of Rochester, we assessed the relationship between platelet and neutrophil engraftment times and patient age, gender, donor source of stem cells, type of graft and the effect of conditioning regimen intensity. We have also assessed the red cell and platelet transfusion frequency in these patients. Although red cell transfusions are generally well tolerated and effective, they do contribute to potential infectious agent exposure and to allergic reactions, transfusion-related lung injury, volume overload and iron overload. 9 Platelet transfusions can also lead to allosensitization and allergic reactions even when products are leukodepleted and irradiated. Some patients are refractory to platelet transfusions in the SCT setting. Thus, means to enhance platelet recovery apart from transfusion would be welcome akin to use of G-CSFs.
PATIENTS AND METHODS
Records of all consecutive adult patients X18 years of age undergoing a first auto-SCT or allo-SCT at the University of Rochester from 2005 through 2009 were evaluated for TBI-containing conditioning regimens and between 2007 and 2009 for non-TBI-containing regimens. This difference in time span allowed a more balanced number of patients between the two groups, whereas supportive care regimens did not vary substantially during these time frames. This study was approved by the Research Subjects Review Board of the University of Rochester. Patients were identified from lists reported to the CIBMTR (Center for International Bone Marrow Transplantation Research) from the University of Rochester. Both the paper chart and the electronic clinical information system were accessed, and once data were collected, patient names were de-identified for data analyses by statisticians. Information obtained from the chart included demographic information, date of transplant, underlying disease, donor source, graft type and conditioning regimen. Days to platelet and neutrophil engraftment were determined as were the number of red cell units and platelet transfusions administered. Platelet engraftment was defined per the CIBMTR as the first of 3 days when the platelet count is X20 Â 10 9 /L without transfusion for 7 days, and/or the first day when the platelet count reaches X100 Â 10 9 /L without transfusion for 7 days (http://www. cibmtr.org/DataManagement/TrainingReference/Manuals/DataManagement/ Documents/post-ted-instruction.pdf). Neutrophil engraftment was also defined per the CIBMTR as the first of three consecutive days where the count reached 40.5 Â 10 9 /L. Nadir was defined as o20 Â 10 9 /L for platelets and o0.1 Â 10 9 /L for neutrophils. Conditioning regimens were grouped based on intensity, and all allo-SCT patients received the usual GVHD prophylaxis (usually tacrolimius and mycophenylate mofetil or short-course MTX) and transplant-related supportive care. All autologous transplant patients received G-CSF, usually beginning on day þ 5 after stem cell infusion, and in allogeneic transplant patients, use of G-CSF was at the discretion of the transplant physician. Per transplant policy, prophylactic platelet transfusions were administered when the platelet count was p10 Â 10 9 /L, except in cases of high fever or bleeding where the threshold would be raised to meet the clinical risk. Over 95% of platelet products utilized at our institution are pooled random donor platelet transfusions. Single donor unmatched and HLA-matched transfusions are rarely used. Red cell transfusions were administered for a hemoglobin level of p8 g/dL unless cardiac or other medical conditions dictated a different transfusion threshold. Each unit of packed red cells administered was counted as a transfusion. All transfused platelets and red cells were leukodepleted and irradiated, and in cases where patients had more than two febrile/allergic reactions, a washed protocol was implemented. Conditioning regimen intensity was defined as high (containing TBI X1200 cGy or BU 16 mg/kg or equivalent), intermediate (containing TBI 400-600 cGy or Fludarabine/Melphalan at X140 mg/m 2 ) and low intensity (containing TBI 200 cGy with fludarabine or fludarabine/ CY/antithymocyte globulin).
Statistical methods
Descriptive statistics including means, s.d. and proportions were reported for all adult patients of X18 years. Multivariate logistic regression analyses modeling the probability of reaching a nadir as a function of the demographic and clinical variables including age, gender, graft type, donor type, disease type and conditioning regimen intensity were performed to compare patients who had a nadir from those who did not. Backward selection procedure was used to select predictors. Odds ratios (ORs) are reported to measure the influence of predictors on the likelihood of reaching a nadir. Contingency analyses and w 2 tests were conducted to perform bivariate analyses of categorical variables. The medians, means and s.d. of numbers of red blood transfusions and platelet transfusions and total number of stem cells infused were computed and compared between groups using Wilcoxon rank-sum tests or Kruskal-Wallis tests. The probability of engraftment was estimated using the method of cumulative incidence, treating death as a competing risk. Gray's tests were used to compare the engraftment rates among groups, specified by donor type, graft type or conditioning regimen intensity. A median engraftment time was defined as the time at which engraftment occurred for half of the patients among those who had engraftment within 100 days. The 25th percentile and 75th percentile of engraftment times were defined in a similar fashion.
Univariate and multivariate Cox regression analyses were used to evaluate the influence of demographic and clinical characteristics (including number of platelet transfusions, number of red blood cell transfusions and number of stem cells infused) on the time to platelet engraftment and on the time to neutrophil engraftment. Hazard ratios (HRs) were reported for those variables. A multiple linear regression analysis was performed on the log-transformed number of transfusions to assess the association between those characteristics and the number of transfusions. All tests were two sided and the significance level (probability of type 1 error) was set at 0.05. Reported P-values were not adjusted for multiple comparisons. Analyses were conducted using the SAS statistical package, version 9.13 (SAS Institute, Cary, NC, USA) and MatLab version 7.11 (MathWorks, Inc., Natick, MA, USA). Table 1 Platelet and neutrophil engraftment A total of 456 patients were analyzed for platelet engraftment after exclusion of 49 patients who did not have a nadir of the platelet count. Of these 49 patients without platelet count nadir, 16 were myeloma patients, all of whom received high-dose melphalan and autologous PBSC grafts. Of the 49 patients, 16 were allogeneic transplant patients who received low-intensity Each patient was followed up to 100 days to determine whether either platelet engraftment or neutrophil engraftment had occurred. Table 2 shows the median and mean number of days to platelet and neutrophil engraftment based on donor type. The proportion of patients who had platelet engraftment within 100 days was estimated as 96.3% (autologous), 88.1% (related allogeneic) and 72.3% (MUD). The median time to platelet engraftment for those who had a nadir and had platelet engraftment within 100 days was 17 days (range 7-91 days). Figure 1 shows estimates of the cumulative incidence functions for the time to platelet engraftment (top panel) and for the time to neutrophil engraftment (bottom panel) by donor type (auto vs related allo vs MUD), graft type (PBSCs vs cord vs BM) and conditioning regimen intensity (low vs intermediate vs high). The cumulative incidence functions of the time to platelet engraftment and of the time to neutrophil engraftment were found significantly associated with donor type, graft type and conditioning regimen intensity (all P-values o0.001; Gray's test). Multivariate analyses based on a Cox proportional hazard model including graft type, donor type and conditioning regimen intensity as independent variables also suggested that graft type (P ¼ 0.0005; BM vs PBSC HR ¼ 0.53; cord vs PBSC HR ¼ 0.31) and donor type (Po0.0001; allo vs MUD HR ¼ 1.6; auto vs MUD HR ¼ 2.2) might influence the rate of platelet engraftment. However, conditioning regimen intensity did not remain significantly associated with the time to platelet engraftment when adjusting for donor type and graft type (P ¼ 0.52). In a similar analysis, we found that the time to neutrophil engraftment was significantly affected by graft type (P ¼ 0.005; BM vs PBSC HR ¼ 0.51; cord vs PBSC HR ¼ 0.57) and donor type (Po0.0001; allo vs MUD HR ¼ 1.3; auto vs MUD HR ¼ 2.3). The relationship with conditioning regimen intensity was close to significant (P ¼ 0.08).
RESULTS

Patient characteristics
Bivariate analyses looking at the association between conditioning regimen intensity and graft type, as well as between conditioning regimen intensity and donor type, indicated that conditioning regimen intensity was strongly associated with donor type (Po0.001) and that patients who received high conditioning regimen intensity were more likely to receive autologous transplant. It is therefore possible that the difference observed between the times to platelet engraftment among conditioning regimen intensities can be partly attributed to differences between donor types. No significant association was found between conditioning regimen intensity and graft type (P ¼ 0.30).
Regimen intensity was a significant predictor of platelet count engraftment (Po0.001), but patients with high or intermediate regimen intensity included all the autograft patients, and hence the cumulative incidence rates of engraftment were consistently higher over time, corresponding to faster rates of engraftment, than those with low regimen intensity.
Transfusion requirements
The mean number (s.d.) of RBC units transfused for each level of clinical factor characteristic is shown in Table 3 . The multivariate linear regression analysis of clinical factors affecting the number of RBC units transfused up to 100 days suggested that gender, donor type, disease type, conditioning regimen intensity and TBI were significant. More specifically, female gender, unrelated donor transplant, leukemia, high conditioning regimen intensity and receiving TBI were associated with higher need for RBC unit transfusion. The number of transfusions administered was not affected by age, CD34 þ (stem) cell number infused or graft type.
In the analysis of clinical factors affecting the number of platelet transfusions required up to 100 days of transplant, graft type, donor type, disease type, conditioning regimen intensity and TBI were found to be significant (Table 4) . BM or cord blood transplant, unrelated donor transplant, leukemia, high conditioning regimen intensity and receiving TBI were associated with higher number of platelet transfusions. To determine that the effect of regimen intensity was not explained by auto-SCTs being included in the high-intensity category, we examined the effect of conditioning regimen intensity on the number of transfusions for all allogeneic (related and MUD) transplants combined. Compared with patients receiving low-intensity conditioning regimens, patients undergoing related and unrelated allogeneic transplants with high-intensity conditioning regimens required higher numbers of platelet transfusions (P ¼ 0.044). It is also highly suggestive that patients with high-intensity conditioning regimens required higher numbers of RBC transfusions (P ¼ 0.067). Abbreviations: Allo ¼ allogeneic; Auto ¼ autologous; MUD ¼ matched unrelated donor.
Factors affecting engraftment and transfusion needs in SCT J Liesveld et al
To determine that factors affecting transfusion requirements were not influenced by whether the transplant was autologous or allogeneic (related and MUD transplants), we included interaction terms between transplant type (autologous vs allogeneic ) and all other variables entered in the model from the previous bivariate analysis. For the number of RBC units transfused, none of the interaction terms were found to be statistically significant at the 5% level (P40.18). For the number of platelet transfusions, this analysis also demonstrated NS terms (P40.17), except for the interaction term between age and transplant type (P ¼ 0.042) that, when adjusted for multiple testing (8 interactions), were also no longer significant. There was therefore little evidence that factors associated with transfusion differed between auto-SCT and alloSCTs in the first 100 days. Likewise, similar analysis showed no influence of disease type on the number of transfusions for each transplant type analyzed separately (P ¼ 0.60 for red cell units transfused and P ¼ 0.55 for platelet transfusions). Similar analysis did not demonstrate significance for ABO incompatibility in alloSCTs (P ¼ 0.34 for red cell units transfused and P ¼ 0.75 for number of platelet transfusions). Finally, disease recurrence before day 100 had no independent effect on red cell units transfused (P40.12) or for platelets transfused (P40.10).
DISCUSSION
Transfusions are nearly always utilized in the setting of SCT, although in patients with religious objections to transfusion, use of the so-called 'bloodless transplants' has been successfully accomplished with acceptable mortality in carefully selected patients. 10 Transfusion considerations vary in the pre, peri and post transplant settings. 11 The work reported here demonstrates that contemporary SCT remains associated with significant periods of thrombocytopenia and with need for transfusion support with both red cells and platelets, even when using currently recommended thresholds of hemoglobin of 8 g/dL and platelets of 10 Â 10 9 /L to trigger transfusion. We restricted our analysis to first transplants because second transplants have of themselves been associated with increased frequency and duration of transfusion need. 7 Our data showed that time to platelet engraftment was significantly influenced by graft type, donor type and intensity of conditioning regimes. That time to platelet engraftment was influenced by graft type and donor type has been previously reported, with PBSC grafts associated with faster platelet engraftment. 8 Prolonged platelet nadirs can increase morbidity and mortality during transplantation because of increased bleeding risk, and platelet transfusions themselves can be associated with allergic and immunologic reactions that can contribute to transplant-related morbidity and mortality. 12 It is now generally accepted that a safe transfusion threshold for platelets is 10 Â 10 9 /L. 13, 14 Recently, use of therapeutic vs prophylactic transfusion has been espoused, but some TBIcontaining regimens required more transfusions because of mucositis when transfusions were utilized only for symptoms or bleeding. 15 Other groups have also found faster engraftment but more gastrointestinal bleeding with this approach. 16 Previous retrospective studies have shown that CD34 þ cell counts in the graft, platelet counts at start of conditioning, local radiation and fever all influence time to platelet recovery. 17 Reduced-intensity transplants have been associated with reduction in platelet transfusion requirements. In one study, the median day of platelet recovery was 9, and 50% of cases required no platelet transfusions. 18 In our population, approximately half of those who received low-intensity regimens did have a platelet nadir. These patients usually had a PBSC graft, and interestingly, in those who did nadir, the time to engraftment was actually longer . This may reflect some of the reliance on immunologic mechanisms to achieve donor chimerism in these settings. The mean number of platelet transfusions was higher in MUD compared with autologous and related donor allogeneic transplants (Po0.001), again suggesting an immunologic effect. Multivariate Cox regression analysis suggested that graft type (PBSC vs marrow, P ¼ 0.045), donor type (P ¼ 0.002) and number of stem cells infused (P ¼ 0.002) were significant regarding platelet engraftment times. However, TBI administration (P ¼ 0.005) and transplants performed for leukemia were also significantly associated with higher numbers of platelet transfusions, suggesting that transfusions were influenced by other clinical factors present before time of stem cell infusion. Possibilities would be fevers, mucositis, increased mucosal bleeding or alterations in the marrow microenvironment affecting megakaryocyte engraftment. These variables were not examined in this retrospective study. Previous studies have also shown that the numbers of RBC units transfused in SCT settings were significantly less in patients undergoing auto-SCT compared with patients undergoing allo-SCT, 19 and that was also the case in our study. (Medians 2 vs 4; Po0.001). The authors concluded that transfusion of blood products is an expensive but integral part of SCT. 19 Acute GVHD, ABO incompatibility and high-risk transplants can be associated with increased RBC transfusion needs, but in this series ABO incompatibility and disease relapse were not significant independent variables related to RBC unit or platelet transfusion needs. Some studies have shown that women have a longer time to RBC transfusion independence, and we found that on average, women required more RBC transfusions than men in multivariable P-values are based on comparisons with baseline levels for categorical variables with three levels or more. Note that this analysis (and the analysis in Table 3 ) does not include three patients with missing information about G-CSF usage or number of stem cells infused and the three patients who received marrow and PBSCs.
Factors affecting engraftment and transfusion needs in SCT J Liesveld et al analysis. Reasons for this difference are uncertain, and numbers of platelet transfusions did not vary based on gender.
Our study shows that significant numbers of transfusions are still utilized in SCT settings. Some of the initial reports of transfusion use in the 1980s and 1990s predated widespread use of PBSC grafts, nonablative transplants and cord blood transplants. 20, 21 In our series from 2004 to 2010, significant transfusion needs are still demonstrated. It would be anticipated that myeloablative transplants require more RBC and platelet transfusions than do reduced-intensity or nonablative transplants. 18 In our series, patients who underwent reducedintensity conditioning regimens were less likely to have a nadir of platelet counts to o20 Â 10 9 /L (Po0.001) and were less likely to require platelet transfusions (Po0.0001). However, in those who had a platelet count nadir, the time to engraftment was actually longer than in those who had high-intensity conditioning regimens. The numbers of RBC and platelet transfusions required were greater among patients receiving high-intensity conditioning regimens, and this was the case when low-intensity allogeneic transplants (related and unrelated) were compared with intermediate-and high-intensity conditioning regimen transplants of the same type. An autologous source of stem cells was also significantly associated with no platelet nadir, and among 259 auto-SCT patients, there were 30 (11.6%) patients who did not require platelet support, 52 (20.0%) did not require RBC support and 13 (5.0%) had no transfusions of either RBCs or platelets.
Umbilical cord blood transplants were performed in only a small number of cases in our series. Time to platelet independence in one large series of cord blood transplants was 41 versus 14 days for PBSC grafts in other allogeneic transplants and 25 vs 13 days for red cell transfusion independence. 7 In this series, cord blood transplant recipients also required more RBC and platelet transfusions than did recipients of other graft types.
G-CSF usage may speed neutrophil engraftment after SCT, but whether this has clinical significance as it relates to fever or infectious complications is uncertain. 22 Erythroid-stimulating agents have not eliminated the need for red cell transfusions in the transplant setting, 22 and in the future, use of TPO-stimulating agents such as eltrombopag, 23 romiplostim 24 or others may be P-values are based on comparisons with baseline levels for categorical variables with three levels or more.
Factors affecting engraftment and transfusion needs in SCT J Liesveld et al able to affect the duration of the platelet nadir and the need for platelet transfusions. This could be particularly important in cord blood transplantation settings where stem cell numbers may be limited and times to platelet engraftment and transfusion independence are longer. Such endeavors may improve both the cost and safety of SCT.
